When Multiple Bugs Strike: The Story of Alice Brennan

When Multiple Bugs Strike: The Story of Alice Brennan

A healthy immune system may be all the protection someone needs to overcome a bacterial infection, but once one disease takes hold, it may beget more illnesses. Such is often the case with Clostridium difficile, a potentially deadly bacterium that can flourish in the wake of other infections. Senior citizens, such as Alice Brennan, are particularly vulnerable and serve as a reminder that new and powerful antibiotics are needed as protection from dangerous bacterial threats.

Alice Brennan was a sharp and mobile 88-year-old woman who lived independently in a two-story home in western New York. In late July 2009, however, Mrs. Brennan felt ill and went to the emergency room. Upon examination, doctors detected methicillin-resistant Staphylococcus aureus in her urinary tract. Also known as MRSA, this multidrug-resistant “superbug” is responsible for an estimated 19,000 deaths and 360,000 hospitalizations each year.1 Because MRSA is more difficult to combat than conventional infections, doctors treated Mrs. Brennan with multiple antibiotics.

Even under such aggressive treatment, her condition worsened, and doctors suspected their patient might be fighting more than just MRSA. Tests confirmed their hunch; she had contracted a C. difficile infection, another disease with few treatment options.

C. difficile resides in the intestines of up to 3 percent of healthy adults without causing any symptoms. That can change if a patient takes antibiotics to treat another infection because those drugs may suppress the normal intestinal bacteria that keep C. difficile in check. When circumstances allow C. difficile to flourish, toxins that cause severe diarrhea and inflammation of the colon are released.2 C. difficile-associated infections claimed the lives of nearly 45,000 Americans over an 11-year period, climbing from 793 deaths in 1999 to 7,285 in 2009.3

On August 22, after enduring four ineffective courses of antibiotic treatments, Mrs. Brennan was transferred to a hospice, where she died from complications related to her infections one week later.

Says her daughter, Mary Brennan Taylor, “If there was a magic pill that would have been able to turn this around, I would have given my right arm for that.”

In May 2011, the U.S. Food and Drug Administration approved a new antibiotic to treat infections associated with C. difficile, some strains of which had become resistant to existing treatments.4 As bacteria continue to evolve and new drug-resistant superbugs emerge, Mrs. Brennan's story makes evident the ongoing need for new lifesaving antibiotics.


1 Agency for Healthcare Research and Quality, “Infections with Methicillin-Resistant Staphylococcus Aureus (MRSA) in U.S. Hospitals, 1993–2005,” Center for Delivery, Organization, and Markets, Healthcare Costs and Utilization Project, Nationwide Inpatient Sample, 1993–2005.
2 R. Ricciardi et al., “Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States,” Arch Surg 142, no. 7 (2007): 624–31, discussion 31; F. Barbut and J. C. Petit, “Epidemiology of Clostridium difficile-associated Infections,” Clin Microbiol Infect 7, no. 8 (2001): 405–10; V. K. Viswanathan, M. J. Mallozzi, and G. Vedantam, “Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions,” Gut Microbes 1, no. 4 (2010): 234–42.
3 National Vital Statistics System, Centers for Disease Control and Prevention, “GMWKI: Total deaths for each cause by 5-year age groups, United States, 1999–2006+,” last updated November 12, 2009, www.cdc.gov/nchs/nvss/mortality/gmwki.htm; J. Xu et al., “Deaths: Final Data for 2007,” National Vital Statistics Reports 58, no. 19 (2010); K.D. Kochanek et al., “Deaths: Preliminary Data for 2009,” National Vital Statistics Reports 59, no. 4 (2011).
4 T. Pelaez et al., “Reassessment of Clostridium Difficile Susceptibility to Metronidazole and Vancomycin,” Antimicrob Agents Chemother 46, no. 6 (2002): 1647–50; A. Dworczynski, B. Sokol, and F. Meisel-Mikolajczyk, “Antibiotic resistance of Clostridium difficile isolates,” Cytobios 65, no. 262–263 (1991).

Spotlight on Mental Health

Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.

Explore Pew’s new and improved
Fiscal 50 interactive

Your state's stats are more accessible than ever with our new and improved Fiscal 50 interactive:

  • Maps, trends, and customizable charts
  • 50-state rankings
  • Analysis of what it all means
  • Shareable graphics and downloadable data
  • Proven fiscal policy strategies


Welcome to the new Fiscal 50

Key changes include:

  • State pages that help you keep track of trends in your home state and provide national and regional context.
  • Interactive indicator pages with highly customizable and shareable data visualizations.
  • A Budget Threads feature that offers Pew’s read on the latest state fiscal news.

Learn more about the new and improved Fiscal 50.